A Phase 3 interventional study of Mirikizumab and Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Completed at 580 sites in 34 countries. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.
Among the 10 studies testing mirikizumab in Crohn Disease, this one has the largest enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 2nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
Alimentiv Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 15 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2019.
This study's enrollment of 1,158 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 150 across the 10 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Crohn Disease by Eli Lilly and Company: 6 open now, 7 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one has the largest enrollment, is the only one that started in 2019, is one of 5 in phase 3, and was the 2nd registered.
Eli Lilly and Company’s Crohn Disease studies by the year they started, since 2016.
2 of the studies testing mirikizumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06997965Alimentiv Inc.Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | 2027-09-01 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing mirikizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Placebo intravenously (IV) or subcutaneously (SC) every 4 weeks (Q4W). Any participant in the placebo arm who was considered a non-responder at Week 12 received 900 mg Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W for the remainder of the study. Nonresponse is defined as failing to achieve at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) and be no worse than baseline.
Drug: Placebo
Participants received 900 milligrams (mg) Mirikizumab IV Q4W for 3 doses, then 300 mg SC Q4W
Drug: Mirikizumab
Participants received 6 mg/kg Ustekinumab IV for one dose, then 90 mg SC every 8 weeks (Q8W)
Drug: Ustekinumab
Participants received open label 900 mg Mirikizumab IV for 3 doses, then 300 mg SC Q4W
Drug: Mirikizumab
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Administered IV
Administered SC
Administered IV
Administered SC
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)
Clinical response by patient reported outcome (PRO) defined as ≥30% decrease in stool frequency (SF) and/or abdominal pain (AP) \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Endoscopic response defined as ≥50% reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; \>2 cm=3); extent of ulcerated surface (none=0; \<10%=1; 10% to 30%=2; \>30%=3); extent of affected surface (none=0; \<50%=1; 50% to 75%=2; \>75%=3); presence \& type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 12 to Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)
Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as Crohn's Disease Activity Index (CDAI) total score \<150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]).. Total score range of 0 to 600 points.
Time frame: Week 12 to Week 52
Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)
Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 12
Percentage of Adult Participants Achieving Endoscopic Response at Week 52
Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)
Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.
Time frame: Week 12
Percentage of Adult Participants Achieving Clinical Remission at Week 52
Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.
Time frame: Week 52
Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)
Endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1.
Time frame: Week 12
Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)
The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).
Time frame: Baseline, Week 12
Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)
The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).
Time frame: Baseline, Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)
Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical Remission by PRO defined as SF≤3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤1 and no worse than baseline.
Time frame: Week 12 to Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)
Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Endoscopic remission=SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3);extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3);presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56;higher scores indicating more severe disease. No subscore \>1=no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1
Time frame: Week 12 to Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)
Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points. Corticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.
Time frame: Week 12 to Week 52
Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)
Change from baseline in CRP
Time frame: Baseline, Week 52
Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)
Change from baseline in Fecal Calprotectin
Time frame: Baseline, Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)
Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).
Time frame: Week 12 to Week 52
Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)
Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).
Time frame: Week 12 to Week 52
Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)
The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.
Time frame: Baseline, Week 52
Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab
PopPK: AUC of Mirikizumab
Time frame: 900 mg Mirikizumab: Week 4: Predose; Week 4, Day 1: Postdose; Week 8, 12: Predose 300 mg Mirikizumab: Week 16, 24, 36: Predose; Week 52
| Milestone | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescents) |
|---|---|---|---|---|
| Started | 212 | 631 | 309 | 6 |
| Received at least one dose of study drug | 211 | 630 | 309 | 6 |
| Placebo non-responder at week 12 | 85 | 0 | 0 | 0 |
| Completed | 159 | 561 | 271 | 4 |
| Not completed | 53 | 70 | 38 | 2 |
| Withdrew: Adverse event | 9 | 11 | 2 | 0 |
| Withdrew: Death | 2 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 14 | 11 | 7 | 1 |
| Withdrew: Lost to follow-up | 0 | 7 | 1 | 0 |
| Withdrew: As reported by investigator | 2 | 6 | 6 | 0 |
| Withdrew: Physician decision | 3 | 2 | 1 | 0 |
| Withdrew: Pregnancy | 2 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 20 | 28 | 18 | 1 |
| Withdrew: Non-compliance | 1 | 1 | 0 | 0 |
| Withdrew: Disposition not captured | 0 | 2 | 1 | 0 |
Clinical response by patient reported outcome (PRO) defined as ≥30% decrease in stool frequency (SF) and/or abdominal pain (AP) \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Endoscopic response defined as ≥50% reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; \>2 cm=3); extent of ulcerated surface (none=0; \<10%=1; 10% to 30%=2; \>30%=3); extent of affected surface (none=0; \<50%=1; 50% to 75%=2; \>75%=3); presence \& type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) | 9.0 (5.1 to 13.0) | 38.0 (34.0 to 42.0) |
Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as Crohn's Disease Activity Index (CDAI) total score \<150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]).. Total score range of 0 to 600 points.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) | 19.6 (14.1 to 25.1) | 45.4 (41.4 to 49.5) |
Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab) | 12.6 (8.0 to 17.2) | 32.5 (28.7 to 36.3) |
Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | Placebo | Mirikizumab | Ustekinumab |
|---|---|---|---|
| Percentage of Adult Participants Achieving Endoscopic Response at Week 52 | 9 (5.1 to 13.0) | 48.4 (44.3 to 52.4) | 46.3 (40.6 to 52.1) |
Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab) | 25.1 (19.1 to 31.2) | 37.7 (33.7 to 41.6) |
Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points.
| percentage of participants | Placebo | Mirikizumab | Ustekinumab |
|---|---|---|---|
| Percentage of Adult Participants Achieving Clinical Remission at Week 52 | 19.6 (14.1 to 25.1) | 54.1 (50.0 to 58.1) | 48.4 (42.7 to 54.2) |
Endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab) | 4.0 (1.3 to 6.7) | 10.9 (8.3 to 13.4) |
The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).
| score on a scale | Placebo | Mirikizumab |
|---|---|---|
| Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab) | -1.58 ± 0.168 | -2.44 ± 0.099 |
The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).
| score on a scale | Placebo | Mirikizumab |
|---|---|---|
| Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab) | -1.23 ± 0.180 | -3.24 ± 0.106 |
Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical Remission by PRO defined as SF≤3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤1 and no worse than baseline.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab) | 19.6 (14.1 to 25.1) | 45.4 (41.4 to 49.5) |
Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Endoscopic remission=SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3);extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3);presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56;higher scores indicating more severe disease. No subscore \>1=no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \>1
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab) | 2.0 (0.1 to 4.0) | 15.9 (12.9 to 18.9) |
Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe). Clinical remission defined as CDAI total score \<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \[hematocrit\]). Total score range of 0 to 600 points. Corticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab) | 18.6 (13.2 to 24.0) | 43.7 (39.7 to 47.7) |
Change from baseline in CRP
| milligram per liter (mg/L) | Placebo | Mirikizumab |
|---|---|---|
| Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab) | -0.08 ± 0.087 | -0.93 ± 0.051 |
Change from baseline in Fecal Calprotectin
| micrograms per gram (μg/g) | Placebo | Mirikizumab |
|---|---|---|
| Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab) | -0.19 ± 0.117 | -1.41 ± 0.067 |
Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab) | 14.6 | 43.2 |
Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab) | 16.7 (0.0 to 33.9) | 21.1 (8.1 to 34.0) |
The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.
| score on a scale | Placebo | Mirikizumab |
|---|---|---|
| Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab) | 15.9 ± 2.316 | 43.82 ± 1.365 |
PopPK: AUC of Mirikizumab
| micrograms*day per milliliter(ug*day/mL) | 900 mg Mirikizumab IV Q4W | 300 mg Mirikizumab SC Q4W |
|---|---|---|
| Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab | 1820 ± 38.1 | 220 ± 55.9 |
Alternate endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \>2 cm = 3); extent of ulcerated surface (none = 0; \<10% = 1; 10% to 30% = 2; \>30% = 3); extent of affected surface (none = 0; \<50% = 1; 50% to 75% = 2; \>75% = 3); presence \& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no subscore \>1 in any of the 20 individual variables.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Alternate Endoscopic Remission at Week 12 (Placebo and Mirikizumab) | 7.0 (1.9 to 12.1) | 17.6 (13.2 to 22.1) |
Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Alternate endoscopic remission defined as SES-CD Total Score ≤4 \& at least 2-point reduction from baseline \& no subscore \>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \& each of 20 individual variables scored 0-3: presence \& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\>2 cm=3); extent of ulcerated surface (none=0;\<10%=1;10% to 30%=2;\>30%=3);extent of affected surface (none=0;\<50%=1;50% to 75%=2;\>75%=3); presence \& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no subscore \>1 in any of the 20 individual variables.
| percentage of participants | Placebo | Mirikizumab |
|---|---|---|
| Percentage of Adult Participants Achieving Clinical Response at Week 12 and Alternate Endoscopic Remission at Week 52 (Placebo and Mirikizumab) | 4.0 (0.1 to 7.9) | 23.5 (18.5 to 28.4) |
Collected over Baseline up to follow up (up to 68 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/211 (0.5%) | 37/211 (17.5%) | 66/211 (31.3%) |
| Placebo Non-Responders | 1/85 (1.2%) | 7/85 (8.2%) | 27/85 (31.8%) |
| Mirikizumab | 0/630 (0%) | 65/630 (10.3%) | 300/630 (47.6%) |
| Ustekinumab | 1/309 (0.3%) | 35/309 (11.3%) | 131/309 (42.4%) |
| Mirikizumab (Adolescents) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Placebo | Placebo Non-Responders | Mirikizumab | Ustekinumab | Mirikizumab (Adolescents) |
|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 14/211 | 2/85 | 12/630 | 11/309 | 0/6 |
| Anal fistulaGastrointestinal disorders | 4/211 | 0/85 | 0/630 | 1/309 | 0/6 |
| IleusGastrointestinal disorders | 0/211 | 1/85 | 2/630 | 1/309 | 0/6 |
| Intestinal obstructionGastrointestinal disorders | 1/211 | 1/85 | 3/630 | 0/309 | 0/6 |
| Intestinal perforationGastrointestinal disorders | 0/211 | 1/85 | 0/630 | 0/309 | 0/6 |
| Procedural intestinal perforationInjury, poisoning and procedural complications | 0/211 | 1/85 | 0/630 | 0/309 | 0/6 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/211 | 1/85 | 0/630 | 0/309 | 0/6 |
| SalpingitisInfections and infestations | 1/86 | 0/37 | 0/274 | 0/161 | 0/3 |
| Abdominal painGastrointestinal disorders | 2/211 | 0/85 | 2/630 | 0/309 | 0/6 |
| Bile duct stoneHepatobiliary disorders | 2/211 | 0/85 | 0/630 | 0/309 | 0/6 |
| Event | Placebo | Placebo Non-Responders | Mirikizumab | Ustekinumab | Mirikizumab (Adolescents) |
|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 21/211 | 4/85 | 17/630 | 14/309 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 8/211 | 1/85 | 33/630 | 12/309 | 1/6 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/211 | 0/85 | 11/630 | 2/309 | 1/6 |
| VomitingGastrointestinal disorders | 2/211 | 2/85 | 24/630 | 6/309 | 1/6 |
| PyrexiaGeneral disorders | 5/211 | 2/85 | 27/630 | 9/309 | 1/6 |
| HypersensitivityImmune system disorders | 1/211 | 0/85 | 3/630 | 2/309 | 1/6 |
| Covid-19Infections and infestations | 21/211 | 6/85 | 103/630 | 46/309 | 1/6 |
| Epstein-barr virus infectionInfections and infestations | 0/211 | 0/85 | 0/630 | 0/309 | 1/6 |
| GastroenteritisInfections and infestations | 5/211 | 0/85 | 15/630 | 8/309 | 1/6 |
| PharyngotonsillitisInfections and infestations | 0/211 | 0/85 | 0/630 | 0/309 | 1/6 |
Adults: All randomized participants; Adolescents: All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescent) | Total |
|---|---|---|---|---|---|
| <=18 years | 4 | 11 | 6 | 6 | 27 |
| Between 18 and 65 years | 205 | 598 | 295 | 0 | 1098 |
| >=65 years | 3 | 22 | 8 | 0 | 33 |
| Sex: Female, Male(Participants) | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescent) | Total |
|---|---|---|---|---|---|
| Female | 87 | 274 | 161 | 3 | 525 |
| Male | 125 | 357 | 148 | 3 | 633 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescent) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 6 | 0 | 18 |
| Not Hispanic or Latino | 16 | 58 | 25 | 0 | 99 |
| Unknown or Not Reported | 192 | 565 | 278 | 6 | 1041 |
| Race (NIH/OMB)(Participants) | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescent) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 2 | 0 | 6 |
| Asian | 44 | 158 | 78 | 2 | 282 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 12 | 8 | 0 | 25 |
| White | 155 | 448 | 219 | 4 | 826 |
| More than one race | 0 | 3 | 1 | 0 | 4 |
| Unknown or Not Reported | 6 | 8 | 1 | 0 | 15 |
| Region of Enrollment(Participants) | Placebo | Mirikizumab | Ustekinumab | Mirikizumab (Adolescent) | Total |
|---|---|---|---|---|---|
| United States | 20 | 66 | 31 | 0 | 117 |
| Czechia | 11 | 29 | 17 | 0 | 57 |
| Russia | 22 | 44 | 20 | 0 | 86 |
| Austria | 0 | 7 | 3 | 0 | 10 |
| Latvia | 0 | 1 | 2 | 0 | 3 |
| Netherlands | 1 | 2 | 1 | 0 | 4 |
| South Korea | 7 | 40 | 11 | 2 | 60 |
| China | 31 | 90 | 43 | 0 | 164 |
| Brazil | 11 | 29 | 18 | 0 | 58 |
| Poland | 28 | 83 | 47 | 3 | 161 |
| Slovakia | 2 | 10 | 7 | 0 | 19 |
| France | 3 | 3 | 1 | 0 | 7 |
| Lithuania | 1 | 3 | 1 | 0 | 5 |
| Serbia | 8 | 7 | 6 | 0 | 21 |
| Croatia | 1 | 6 | 0 | 0 | 7 |
| Argentina | 0 | 2 | 0 | 0 | 2 |
| Romania | 1 | 10 | 2 | 0 | 13 |
| Hungary | 5 | 19 | 10 | 0 | 34 |
| Japan | 4 | 11 | 13 | 0 | 28 |
| Ukraine | 12 | 43 | 33 | 0 | 88 |
| United Kingdom | 0 | 4 | 1 | 0 | 5 |
| Switzerland | 1 | 3 | 3 | 0 | 7 |
| India | 2 | 13 | 10 | 0 | 25 |
| Spain | 1 | 3 | 0 | 0 | 4 |
| Canada | 8 | 19 | 8 | 0 | 35 |
| Turkey | 6 | 28 | 7 | 0 | 41 |
| Belgium | 2 | 5 | 2 | 0 | 9 |
| Denmark | 0 | 2 | 0 | 0 | 2 |
| Italy | 3 | 4 | 0 | 1 | 8 |
| Mexico | 1 | 4 | 2 | 0 | 7 |
| Israel | 4 | 9 | 2 | 0 | 15 |
| Australia | 8 | 10 | 0 | 0 | 18 |
| Germany | 8 | 22 | 8 | 0 | 38 |
Showing the first 100 of 580 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2019 to primary completion in Aug 2023, 49 months.
Results were first posted in Dec 2024, 1 year 4 months after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 49 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab